ClinicalTrials.gg
CompletedNCT04921345Updated Jun 25, 2026Results posted

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

A Phase 2 interventional study of Nemolizumab and Nemolizumab in Moderate-to-Severe Atopic Dermatitis, sponsored by Galderma R&D. Completed at 23 sites in 5 countries. Open to participants aged 2 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
109
Allocation
Non-randomized
Ages
2 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing nemolizumab in Dermatitis, Atopic — 3 open to participants now, 3 under way, 1 of them phase 3. nemolizumab · Dermatitis, Atopic.

Enrollment
9th of 14
109 · median 209
Started
2021
with 1 other
Phase 2
7 of 14
1 open now
Registered
9th of 14
by date
Lead sponsor
12 of 14
Galderma R&D

Among the 14 studies testing nemolizumab in Dermatitis, Atopic, this one is the 9th largest by enrollment, is one of 2 that started in 2021, is one of 7 in phase 2, and was the 9th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 14 studies testing nemolizumab in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nemolizumab

nemolizumab: first FDA approval 2024 (NEMLUVIO), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 2 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing nemolizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this study was to assess the pharmacokinetics (PK), safety, and efficacy of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).

03

Conditions studied

  • Moderate-to-Severe Atopic Dermatitis

Browse trials for

Keywords

  • Atopic Dermatitis
  • Nemolizumab
  • CD14152
04

Who can participate

Ages eligible
2 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic AD that has been documented for at least 6 months for participants aged 2-6 years and at least 1 year for participants aged 7-11 years before the screening visit and confirmed according to the American Academy of Dermatology Consensus Criteria at the time of the screening visit
  • EASI score >=16 at both screening and baseline visits
  • IGA score >=3 at both screening and baseline visits
  • AD involvement >=10% of BSA at both screening and baseline visits
  • Peak (maximum) PP NRS score of at least 4.0 at both screening and baseline visits
  • Agree to apply a moisturizer throughout the study from the screening visit daily, and liberally as needed; agree to apply an authorized topical (TCS) from the screening visit and throughout the study as determined appropriate by the investigator
  • Participant and caregiver willing and able to comply with all of the time commitments and procedural requirements of the clinical trial protocol
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Body weight less than 10 kilogram (kg)
  • Child in Care: a child who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation
  • Participants with a current medical history of chronic bronchitis
  • Requiring rescue therapy for AD during the run-in period or expected to require rescue therapy within 2 weeks following the baseline visit
  • Positive serology results for surface antigen (HBsAg) or hepatitis B core antibody (HBcAb), (HCV) antibody with positive confirmatory test for HCV (example; polymerase chain reaction [PCR]), or (HIV) antibody at the screening visit
  • History of lymphoproliferative disease, (including anaphylaxis) to an immunoglobulin product and intolerance to low or mid potency topical
  • Known or suspected
  • Participants unwilling to refrain from using prohibited medications during the clinical trial.
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    Cohort 1: Participants aged 7-11 year

    Participants aged 7-11 years will receive nemolizumab for 52 weeks.

    Drug: Nemolizumab

  • Experimental
    Cohort 1.1: Participants aged 7-11 years

    Participants aged 7-11 years will receive nemolizumab for 52 weeks.

    Drug: Nemolizumab

  • Experimental
    Cohort 2: Participants aged 2-6 years

    Participants aged 2-6 years will receive nemolizumab for 52 weeks.

    Drug: Nemolizumab

Interventions

  • Participants will receive subcutaneous (SC) injection of 10, 20 or 30 milligrams (mg) nemolizumab, every 4 weeks (Q4W) for 52 weeks with a loading dose of 20, 40 or 60 mg at Day 1 based on the body weight.

    Also known as: CD14152

  • Participants will receive SC injection of 5, 10 or 15 mg nemolizumab, Q4W for 52 weeks with a loading dose of 10, 20 or 30 mg at Day 1 based on the body weight.

    Also known as: CD14152

06

What researchers measure

Primary outcomes

  1. Nemolizumab Serum Concentrations

    Serum concentrations of Nemolizumab were analyzed using validated enzyme linked immunosorbent assay (ELISA).

    Time frame: At Weeks 4, 8, 12, 16, 32 and 52

  2. Apparent Total Body Clearance (Cl/F) of Nemolizumab

    CL/F is apparent clearance of the drug from the serum, calculated as the drug dose divided area under the curve from time 0 extrapolated to infinite time \[AUC (0-inf)\]. Individual nemolizumab.

    Time frame: Pre-dose at Weeks 4, 8, 12, 16, 32 and 52

  3. Apparent Volume of Distribution (Vd/F) of Nemolizumab

    Vd/F was calculated as dose divided by lambda\_z \*AUC(0-inf).

    Time frame: Pre-dose at Weeks 4, 8, 12, 16, 32 and 52

  4. Absorption Rate Constant (Ka) of Nemolizumab

    Time frame: Pre-dose at Weeks 4, 8, 12, 16, 32 and 52

  5. Serum Concentration Observed Immediately Before Next Dosing (Ctrough) of Nemolizumab

    Time frame: Pre-dose at Weeks 4, 8, 12, and 16

  6. Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Nemolizumab

    Time frame: Pre-dose at Weeks 4, 8, 12, 16, 32 and 52

  7. Apparent Terminal Half-life (t1/2) of Nemolizumab

    Time frame: Pre-dose at Weeks 4, 8, 12, 16, 32 and 52

  8. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs), Adverse Events Leading to Discontinuation and Serious Adverse Events (SAEs)

    AE defined as any untoward medical occurrence in clinical study participant administered a medicinal product which does not necessarily have causal relationship with this treatment. TEAEs defined as AEs occurring after first administration of study drug during the study. SAE was any untoward medical occurrence, in view of either Investigator or Sponsor, that resulted in death, was life-threatening, resulted in inpatient hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was important medical event. AESI was noteworthy TEAE for study drug that was to be monitored closely and reported promptly. Relatedness to study drug was based on Investigator's discretion. AEs Leading to study treatment withdrawal and AEs Leading to study withdrawal will also be reported.

    Time frame: Baseline through Week 52

Secondary outcomes

  1. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Each Visit up to Week 52

    EASI assesses severity and extent of AD signs through a composite score of erythema, induration/population, excoriation, and lichenification. The severity was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. The EASI score ranged from 0 to 72 with higher scores representing greater severity of atopic dermatitis.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  2. Absolute Change From Baseline in EASI Score

    EASI assesses severity and extent of AD signs through a composite score of erythema, induration/population, excoriation, and lichenification. The severity was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. The EASI score ranged from 0 to 72 with higher scores representing greater severity of atopic dermatitis.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  3. Number of Participants Achieving 50 Percent (%), 75% or 90% Response From Baseline in EASI (EASI-50, EASI-75 and EASI-90)

    EASI assesses severity and extent of AD signs through a composite score of erythema, induration/population, excoriation, and lichenification. The severity was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. The EASI score ranged from 0 to 72 with higher scores representing greater severity of atopic dermatitis. EASI-50, EASI-75 and EASI-90 responders will be the participants who achieved greater than or equal to (\>=) 50%, \>=75% and \>=90% overall improvement in EASI score respectively from baseline to Week 52.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  4. Number of Participants With Investigator's Global Assessment (IGA) Success Rate

    IGA is a 5-point scale used by the investigator or trained designee to evaluate the global severity of AD. The Investigator reviewed the participant's skin and give a score of 0 (Clear), 1 (Almost clear), 2 (Mild), 3 (Moderate), or 4 (Severe). Here, higher score indicates severe outcome. Success was defined as an IGA of 0 \[Clear\] or 1 \[Almost clear\] and a \>=2-points improvement from baseline. Number of participants with IGA success rate was reported for this outcome measure.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  5. Change From Baseline in Body Surface Area (BSA) Involvement by Atopic Dermatitis (AD)

    BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and reported as a percentage of all major body sections combined. The reported percentage of BSA was combined percentage of all major body sections.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  6. Absolute Change From Baseline in Weekly Average of Peak Pruritus Numeric Rating Scale (PP NRS) Score

    Pruritus NRS is a scale that will be used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  7. Percent Change From Baseline in Weekly Average of PP NRS Score

    Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  8. Percentage of Participants With an Improvement of >= 4 From Baseline in Weekly Average of PP NRS

    Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  9. Absolute Change From Baseline in Weekly Average of Average Pruritus NRS Score

    Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  10. Percent Change From Baseline in Weekly Average of Average Pruritus NRS Score

    Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  11. Absolute Change From Baseline in Weekly Average of Sleep Disturbance NRS Score

    The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicated worse outcome.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  12. Percent Change From Baseline in Weekly Average of Sleep Disturbance NRS Score

    The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicated worse outcome.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  13. Percentage of Participants Receiving Any Rescue Therapy by Rescue Treatment

    Percentage of participants receiving any rescue therapy by rescue treatment was reported.

    Time frame: From Baseline up to Week 52

  14. Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score

    SCORAD is a clinical tool for assessing the severity and the extent of AD signs and symptoms. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranged from 0 (absent disease) to 103 (severe disease), a higher score indicated severe disease.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  15. Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) For Participants >=4 Years of Age

    The DLQI is a validated 10-item questionnaire covering domains including symptoms/feelings, daily activities, leisure, work/school, personal relationships, and treatment. The participant rated each question ranging from 0 (not at all) to 3 (very much) and score ranged from 0 to 30. A higher total score indicated a poorer quality of life (QoL).

    Time frame: Baseline, Week 16 and Week 52

  16. Change From Baseline in Infants' Dermatology Life Quality Index (iDLQI) Score For Participants Less Than (<) 4 Years of Age

    The DLQI is a validated 10-item questionnaire covering domains including symptoms/feelings, daily activities, leisure, work/school, personal relationships, and treatment. The participant rated each question ranging from 0 (not at all) to 3 (very much) and score ranged from 0 to 30. A higher total score indicated a poorer QoL.

    Time frame: Baseline, Week 16 and Week 52

  17. Change From Baseline in Patient-Oriented Eczema Measure (POEM)

    The POEM is a 7-item questionnaire that assessed disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease). A high score indicated poor QOL.

    Time frame: Baseline, Week 16 and Week 52

  18. Pharmacokinetic (PK)/Pharmacodynamic (PD) Relationship Between Nemolizumab Serum Concentration and Changes in PP NRS

    The relationship between nemolizumab serum concentrations and changes in PP-NRS score was established using population point estimate of IC50, where IC50 is the concentration leading to half of the maximum drug-induced reduction (Imax) in PP NRS.

    Time frame: Baseline up to Week 52

  19. PK/PD Relationship Between Nemolizumab Serum Concentration and Changes in EASI Score

    The relationship between nemolizumab serum concentrations and changes in EASI score was established using population point estimate of IC50. Where, IC50 is the concentration leading to half of the maximum drug-induced reduction (Imax) in EASI score.

    Time frame: Baseline up to Week 52

  20. PK/PD Relationship Between Nemolizumab Serum Concentration and Changes in IGA Score

    The relationship between nemolizumab serum concentrations and changes in IGA score was established using the population point estimate of the slope parameter.

    Time frame: Baseline up to Week 52

  21. Number of Participants With Positive Anti-Drug Antibody (ADA) for Nemolizumab

    ADA positive was defined as a sample that was evaluated as positive in both the ADA screening and confirmatory assays. ADA positive participants was defined as participants who had at least 1 positive ADA result.

    Time frame: Baseline, Week 16 and Week 52

07

Results

Posted May 26, 2026

Participant flow

The study was conducted at 23 sites in the United States, Denmark, Hungary, Poland and Spain from 24 June 2021 to 28 April 2025.

Participant flow — Overall Study
MilestoneCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Started363736
Completed313532
Not completed524
Withdrew: Subject/caregiver request402
Withdrew: Lack of efficacy011
Withdrew: Adverse event100
Withdrew: Lost to follow-up001
Withdrew: Physician/principal investigator decision010

Outcome measures

PrimaryNemolizumab Serum Concentrations

Serum concentrations of Nemolizumab were analyzed using validated enzyme linked immunosorbent assay (ELISA).

Time frame:
At Weeks 4, 8, 12, 16, 32 and 52
Reported as:
Mean · nanograms per milliliters (ng/mL)
Nemolizumab Serum Concentrations
nanograms per milliliters (ng/mL)Cohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Week 45950 ± 22402900 ± 8933080 ± 1220
Week 85150 ± 21502800 ± 9862560 ± 1310
Week 124730 ± 16702550 ± 11802490 ± 1430
Week 164630 ± 16602110 ± 10002430 ± 1510
Week 324370 ± 21002760 ± 11502600 ± 1490
Week 524410 ± 24902250 ± 9392680 ± 1490
PrimaryApparent Total Body Clearance (Cl/F) of Nemolizumab

CL/F is apparent clearance of the drug from the serum, calculated as the drug dose divided area under the curve from time 0 extrapolated to infinite time \[AUC (0-inf)\]. Individual nemolizumab.

Time frame:
Pre-dose at Weeks 4, 8, 12, 16, 32 and 52
Reported as:
Mean · liter per day (L/day)
Apparent Total Body Clearance (Cl/F) of Nemolizumab
liter per day (L/day)Cohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Apparent Total Body Clearance (Cl/F) of Nemolizumab0.139 ± 0.08240.134 ± 0.04070.0761 ± 0.0245
PrimaryApparent Volume of Distribution (Vd/F) of Nemolizumab

Vd/F was calculated as dose divided by lambda\_z \*AUC(0-inf).

Time frame:
Pre-dose at Weeks 4, 8, 12, 16, 32 and 52
Reported as:
Mean · liter
Apparent Volume of Distribution (Vd/F) of Nemolizumab
literCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Apparent Volume of Distribution (Vd/F) of Nemolizumab3.39 ± 1.363.37 ± 1.021.75 ± 0.495
PrimaryAbsorption Rate Constant (Ka) of Nemolizumab
Time frame:
Pre-dose at Weeks 4, 8, 12, 16, 32 and 52
Reported as:
Mean · per day
Absorption Rate Constant (Ka) of Nemolizumab
per dayCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Absorption Rate Constant (Ka) of Nemolizumab0.502 ± 0.04020.503 ± 0.02800.494 ± 0.0383
PrimarySerum Concentration Observed Immediately Before Next Dosing (Ctrough) of Nemolizumab
Time frame:
Pre-dose at Weeks 4, 8, 12, and 16
Reported as:
Mean · micrograms per milliliter (ug/mL)
Serum Concentration Observed Immediately Before Next Dosing (Ctrough) of Nemolizumab
micrograms per milliliter (ug/mL)Cohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Week 46.71 ± 2.763.25 ± 1.213.13 ± 1.29
Week 86.38 ± 3.393.15 ± 1.513.20 ± 1.80
Week 125.35 ± 2.462.85 ± 1.432.84 ± 1.38
Week 165.52 ± 2.542.69 ± 1.483.10 ± 1.63
PrimaryArea Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Nemolizumab
Time frame:
Pre-dose at Weeks 4, 8, 12, 16, 32 and 52
Reported as:
Mean · days*nanograms per milliliters
Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Nemolizumab
days*nanograms per millilitersCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Nemolizumab204 ± 61.6101 ± 26.793.2 ± 38.2
PrimaryApparent Terminal Half-life (t1/2) of Nemolizumab
Time frame:
Pre-dose at Weeks 4, 8, 12, 16, 32 and 52
Reported as:
Mean · day
Apparent Terminal Half-life (t1/2) of Nemolizumab
dayCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Apparent Terminal Half-life (t1/2) of Nemolizumab17.7 ± 3.8917.8 ± 3.8616.9 ± 5.06
PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs), Adverse Events Leading to Discontinuation and Serious Adverse Events (SAEs)

AE defined as any untoward medical occurrence in clinical study participant administered a medicinal product which does not necessarily have causal relationship with this treatment. TEAEs defined as AEs occurring after first administration of study drug during the study. SAE was any untoward medical occurrence, in view of either Investigator or Sponsor, that resulted in death, was life-threatening, resulted in inpatient hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was important medical event. AESI was noteworthy TEAE for study drug that was to be monitored closely and reported promptly. Relatedness to study drug was based on Investigator's discretion. AEs Leading to study treatment withdrawal and AEs Leading to study withdrawal will also be reported.

Time frame:
Baseline through Week 52
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs), Adverse Events Leading to Discontinuation and Serious Adverse Events (SAEs)
ParticipantsCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
TEAEs303232
AESIs431
AE leading to discontinuation100
SAEs000
SecondaryPercent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Each Visit up to Week 52

EASI assesses severity and extent of AD signs through a composite score of erythema, induration/population, excoriation, and lichenification. The severity was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. The EASI score ranged from 0 to 72 with higher scores representing greater severity of atopic dermatitis.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Mean · percent change
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Each Visit up to Week 52
percent changeCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Week 4-48.91 ± 32.283-66.10 ± 32.089-68.88 ± 30.549
Week 8-61.40 ± 36.260-74.65 ± 28.423-75.41 ± 35.869
Week 12-66.89 ± 33.873-80.49 ± 19.318-85.00 ± 19.401
Week 16-76.34 ± 25.119-85.86 ± 14.305-82.17 ± 24.537
Week 20-78.31 ± 23.574-87.26 ± 15.473-88.80 ± 22.292
Week 24-78.39 ± 25.594-92.62 ± 9.826-87.38 ± 21.716
Week 28-82.38 ± 19.766-88.32 ± 15.212-93.28 ± 14.285
Week 32-79.09 ± 29.339-91.72 ± 9.358-88.77 ± 18.080
Week 36-84.49 ± 18.584-88.90 ± 15.773-90.40 ± 15.204
Week 40-87.48 ± 13.801-88.63 ± 15.316-87.16 ± 20.753
Week 44-91.51 ± 10.145-87.08 ± 21.731-89.06 ± 18.792
Week 48-91.07 ± 11.622-85.49 ± 21.664-90.71 ± 16.472
Week 52-90.86 ± 10.609-85.66 ± 21.397-90.53 ± 20.487
SecondaryAbsolute Change From Baseline in EASI Score

EASI assesses severity and extent of AD signs through a composite score of erythema, induration/population, excoriation, and lichenification. The severity was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. The EASI score ranged from 0 to 72 with higher scores representing greater severity of atopic dermatitis.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Mean · score on a scale
Absolute Change From Baseline in EASI Score
score on a scaleCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Week 4-12.86 ± 9.154-18.90 ± 11.316-17.72 ± 8.449
Week 8-16.56 ± 12.141-20.87 ± 9.960-19.51 ± 10.210
Week 12-18.00 ± 11.880-23.25 ± 9.566-21.95 ± 7.247
Week 16-20.46 ± 10.189-24.27 ± 7.840-21.60 ± 8.357
Week 20-21.12 ± 10.359-24.88 ± 8.290-23.34 ± 8.401
Week 24-21.19 ± 10.950-26.63 ± 8.783-22.89 ± 8.483
Week 28-22.06 ± 9.332-25.10 ± 8.529-24.39 ± 7.567
Week 32-21.04 ± 10.940-25.98 ± 8.246-23.48 ± 8.586
Week 36-22.67 ± 9.470-25.30 ± 9.270-23.78 ± 7.532
Week 40-23.26 ± 9.041-25.44 ± 9.533-23.03 ± 8.323
Week 44-24.40 ± 9.259-25.18 ± 9.720-23.44 ± 8.263
Week 48-24.45 ± 9.029-24.33 ± 9.500-23.91 ± 7.981
Week 52-24.09 ± 8.791-24.24 ± 10.001-23.85 ± 8.138
SecondaryNumber of Participants Achieving 50 Percent (%), 75% or 90% Response From Baseline in EASI (EASI-50, EASI-75 and EASI-90)

EASI assesses severity and extent of AD signs through a composite score of erythema, induration/population, excoriation, and lichenification. The severity was assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. The EASI score ranged from 0 to 72 with higher scores representing greater severity of atopic dermatitis. EASI-50, EASI-75 and EASI-90 responders will be the participants who achieved greater than or equal to (\>=) 50%, \>=75% and \>=90% overall improvement in EASI score respectively from baseline to Week 52.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Count of participants · Participants
Number of Participants Achieving 50 Percent (%), 75% or 90% Response From Baseline in EASI (EASI-50, EASI-75 and EASI-90)
ParticipantsCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Week 4: EASI - 50192529
Week 4: EASI - 75101821
Week 4: EASI - 9031310
Week 8: EASI - 50233130
Week 8: EASI - 75152425
Week 8: EASI - 9081618
Week 12: EASI - 50303132
Week 12: EASI - 75172528
Week 12: EASI - 9091519
Week 16: EASI - 50313432
Week 16: EASI - 75242725
Week 16: EASI - 90121920
Week 20: EASI - 50323430
Week 20: EASI - 75253029
Week 20: EASI - 90131822
Week 24: EASI - 50313431
Week 24: EASI - 75263129
Week 24: EASI - 90162525
Week 28: EASI - 50323332
Week 28: EASI - 75303131
Week 28: EASI - 90192129
Week 32: EASI - 50333530
Week 32: EASI - 75273327
Week 32: EASI - 90152526
Week 36: EASI - 50323430
Week 36: EASI - 75253129
Week 36: EASI - 90182424
Week 40: EASI - 50323432
Week 40: EASI - 75272925
Week 40: EASI - 90182322
Week 44: EASI - 50313230
Week 44: EASI - 75292928
Week 44: EASI - 90222422
Week 48: EASI - 50303232
Week 48: EASI - 75282830
Week 48: EASI - 90212224
Week 52: EASI - 50323332
Week 52: EASI - 75302929
Week 52: EASI - 90222025
SecondaryNumber of Participants With Investigator's Global Assessment (IGA) Success Rate

IGA is a 5-point scale used by the investigator or trained designee to evaluate the global severity of AD. The Investigator reviewed the participant's skin and give a score of 0 (Clear), 1 (Almost clear), 2 (Mild), 3 (Moderate), or 4 (Severe). Here, higher score indicates severe outcome. Success was defined as an IGA of 0 \[Clear\] or 1 \[Almost clear\] and a \>=2-points improvement from baseline. Number of participants with IGA success rate was reported for this outcome measure.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Count of participants · Participants
Number of Participants With Investigator's Global Assessment (IGA) Success Rate
ParticipantsCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Week 451210
Week 891714
Week 12131318
Week 16171517
Week 20131922
Week 24132522
Week 28141723
Week 32152324
Week 36171920
Week 40141920
Week 44191920
Week 48172124
Week 52152124
SecondaryChange From Baseline in Body Surface Area (BSA) Involvement by Atopic Dermatitis (AD)

BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and reported as a percentage of all major body sections combined. The reported percentage of BSA was combined percentage of all major body sections.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Mean · percentage of BSA involvement
Change From Baseline in Body Surface Area (BSA) Involvement by Atopic Dermatitis (AD)
percentage of BSA involvementCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Week 4-12.76 ± 18.358-22.22 ± 19.519-17.66 ± 13.779
Week 8-17.75 ± 21.082-28.34 ± 18.666-23.09 ± 17.492
Week 12-21.15 ± 20.593-32.84 ± 17.714-28.15 ± 15.323
Week 16-25.50 ± 17.463-34.17 ± 15.452-25.34 ± 16.319
Week 20-26.09 ± 20.817-36.46 ± 16.910-29.48 ± 14.698
Week 24-28.66 ± 18.126-37.67 ± 16.934-28.74 ± 15.153
Week 28-29.99 ± 17.461-35.90 ± 16.301-31.82 ± 12.338
Week 32-28.72 ± 17.295-38.15 ± 16.188-30.02 ± 14.152
Week 36-31.82 ± 15.182-37.51 ± 16.869-29.18 ± 13.313
Week 40-33.15 ± 15.673-37.57 ± 17.080-28.65 ± 16.538
Week 44-34.98 ± 17.161-35.42 ± 19.669-28.96 ± 17.460
Week 48-35.49 ± 16.827-36.10 ± 18.255-31.70 ± 14.324
Week 52-34.71 ± 16.319-35.27 ± 17.668-31.15 ± 15.041
SecondaryAbsolute Change From Baseline in Weekly Average of Peak Pruritus Numeric Rating Scale (PP NRS) Score

Pruritus NRS is a scale that will be used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Mean · score on a scale
Absolute Change From Baseline in Weekly Average of Peak Pruritus Numeric Rating Scale (PP NRS) Score
score on a scaleCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Week 4-2.78 ± 2.066-3.03 ± 2.470-4.36 ± 2.902
Week 8-3.91 ± 2.266-4.29 ± 2.292-4.84 ± 2.516
Week 12-4.13 ± 2.167-4.47 ± 2.487-5.03 ± 2.573
Week 16-4.60 ± 2.055-4.90 ± 2.491-5.48 ± 2.454
Week 20-4.22 ± 2.221-4.87 ± 2.259-5.54 ± 2.534
Week 24-4.46 ± 2.264-5.16 ± 2.257-5.85 ± 2.424
Week 28-4.58 ± 2.089-5.40 ± 1.984-5.78 ± 2.439
Week 32-4.71 ± 2.187-5.39 ± 2.069-5.72 ± 2.363
Week 36-4.88 ± 1.995-5.50 ± 2.125-5.94 ± 2.348
Week 40-4.88 ± 1.957-5.41 ± 2.087-6.16 ± 2.256
Week 44-4.65 ± 2.008-5.56 ± 2.186-6.26 ± 1.991
Week 48-4.56 ± 2.120-5.81 ± 2.156-6.46 ± 1.978
Week 52-4.66 ± 2.090-5.62 ± 1.944-6.32 ± 2.129
SecondaryPercent Change From Baseline in Weekly Average of PP NRS Score

Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Mean · percent change
Percent Change From Baseline in Weekly Average of PP NRS Score
percent changeCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Week 4-38.15 ± 27.090-41.48 ± 32.040-57.89 ± 39.240
Week 8-53.41 ± 29.280-58.95 ± 29.795-65.90 ± 33.824
Week 12-57.56 ± 29.073-60.29 ± 30.314-68.08 ± 33.578
Week 16-63.84 ± 27.986-66.58 ± 29.990-74.15 ± 31.042
Week 20-59.75 ± 30.193-67.09 ± 28.155-75.40 ± 32.320
Week 24-62.19 ± 31.021-70.43 ± 26.843-79.15 ± 28.563
Week 28-64.67 ± 28.794-73.91 ± 24.040-78.51 ± 29.041
Week 32-64.67 ± 27.737-73.55 ± 26.034-77.65 ± 28.477
Week 36-68.77 ± 27.082-75.57 ± 26.533-80.28 ± 27.557
Week 40-68.79 ± 26.011-73.64 ± 25.659-82.39 ± 26.173
Week 44-65.80 ± 26.928-75.99 ± 26.893-84.51 ± 22.644
Week 48-64.86 ± 28.322-78.89 ± 25.842-86.72 ± 20.254
Week 52-65.73 ± 27.817-75.85 ± 23.800-84.82 ± 24.430
SecondaryPercentage of Participants With an Improvement of >= 4 From Baseline in Weekly Average of PP NRS

Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Number · percentage of participants
Percentage of Participants With an Improvement of >= 4 From Baseline in Weekly Average of PP NRS
percentage of participantsCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Week 423.531.469.4
Week 844.464.766.7
Week 1250.064.769.4
Week 1658.866.776.5
Week 2054.575.078.1
Week 2459.467.780.6
Week 2860.677.481.8
Week 3258.681.378.8
Week 3666.780.684.4
Week 4069.082.486.2
Week 4461.378.890.0
Week 4865.581.392.0
Week 5265.480.088.5
SecondaryAbsolute Change From Baseline in Weekly Average of Average Pruritus NRS Score

Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Mean · score on a scale
Absolute Change From Baseline in Weekly Average of Average Pruritus NRS Score
score on a scaleCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Week 4-2.46 ± 1.878-2.84 ± 2.286-4.26 ± 2.884
Week 8-3.61 ± 2.030-4.14 ± 2.111-4.64 ± 2.477
Week 12-3.83 ± 1.889-4.28 ± 2.303-4.89 ± 2.569
Week 16-4.27 ± 1.884-4.61 ± 2.363-5.29 ± 2.512
Week 20-4.04 ± 1.831-4.61 ± 2.260-5.29 ± 2.539
Week 24-4.38 ± 1.939-5.01 ± 2.145-5.60 ± 2.411
Week 28-4.32 ± 1.818-5.04 ± 1.977-5.55 ± 2.403
Week 32-4.40 ± 1.909-5.00 ± 2.049-5.48 ± 2.309
Week 36-4.65 ± 1.733-4.96 ± 2.204-5.68 ± 2.301
Week 40-4.59 ± 1.757-5.03 ± 2.108-5.89 ± 2.214
Week 44-4.55 ± 1.738-5.08 ± 2.318-5.96 ± 1.942
Week 48-4.42 ± 1.843-5.30 ± 2.261-6.06 ± 1.992
Week 52-4.53 ± 1.729-5.19 ± 2.054-5.89 ± 2.050
SecondaryPercent Change From Baseline in Weekly Average of Average Pruritus NRS Score

Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicated worse outcome.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Mean · percent change
Percent Change From Baseline in Weekly Average of Average Pruritus NRS Score
percent changeCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Week 4-38.07 ± 28.816-42.77 ± 32.130-60.43 ± 40.923
Week 8-55.69 ± 30.791-62.42 ± 29.260-66.94 ± 34.327
Week 12-59.59 ± 29.263-63.40 ± 29.376-69.71 ± 34.020
Week 16-65.85 ± 28.875-68.84 ± 29.502-75.35 ± 31.973
Week 20-63.23 ± 28.263-69.59 ± 29.258-76.24 ± 32.756
Week 24-66.58 ± 29.303-75.37 ± 25.933-79.72 ± 28.575
Week 28-67.41 ± 27.925-76.56 ± 25.092-80.01 ± 28.807
Week 32-67.17 ± 27.445-76.66 ± 27.287-78.86 ± 27.818
Week 36-72.15 ± 26.282-76.63 ± 28.952-81.52 ± 26.943
Week 40-71.45 ± 25.950-76.29 ± 26.727-83.27 ± 25.987
Week 44-71.06 ± 26.279-77.24 ± 30.172-85.78 ± 21.530
Week 48-69.56 ± 28.108-80.56 ± 28.317-87.22 ± 20.586
Week 52-71.11 ± 26.493-78.63 ± 27.303-85.40 ± 24.213
SecondaryAbsolute Change From Baseline in Weekly Average of Sleep Disturbance NRS Score

The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicated worse outcome.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Mean · score on a scale
Absolute Change From Baseline in Weekly Average of Sleep Disturbance NRS Score
score on a scaleCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Week 4-2.22 ± 1.731-2.87 ± 2.348-4.49 ± 3.038
Week 8-3.22 ± 1.957-4.04 ± 2.022-4.91 ± 2.637
Week 12-3.58 ± 1.875-4.09 ± 2.439-5.26 ± 2.758
Week 16-4.02 ± 1.770-4.43 ± 2.608-5.50 ± 2.590
Week 20-3.90 ± 1.968-4.40 ± 2.459-5.43 ± 2.646
Week 24-4.05 ± 1.947-4.76 ± 2.452-5.79 ± 2.358
Week 28-4.10 ± 1.903-4.87 ± 2.436-5.70 ± 2.382
Week 32-4.24 ± 2.014-4.93 ± 2.435-5.69 ± 2.449
Week 36-4.27 ± 1.948-4.92 ± 2.448-5.75 ± 2.408
Week 40-4.29 ± 1.977-4.97 ± 2.332-5.99 ± 2.338
Week 44-4.22 ± 2.032-5.06 ± 2.454-5.93 ± 2.218
Week 48-4.28 ± 2.013-5.19 ± 2.486-5.98 ± 2.235
Week 52-4.25 ± 1.830-5.02 ± 2.235-5.87 ± 2.262
SecondaryPercent Change From Baseline in Weekly Average of Sleep Disturbance NRS Score

The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicated worse outcome.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Mean · percent change
Percent Change From Baseline in Weekly Average of Sleep Disturbance NRS Score
percent changeCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Week 4-39.21 ± 29.647-42.47 ± 38.448-62.43 ± 39.978
Week 8-56.84 ± 31.138-62.31 ± 29.147-70.03 ± 34.843
Week 12-61.78 ± 28.132-61.71 ± 34.954-73.73 ± 34.420
Week 16-69.67 ± 23.842-66.11 ± 36.736-77.79 ± 31.422
Week 20-68.61 ± 27.927-67.56 ± 35.387-77.67 ± 32.456
Week 24-68.90 ± 28.233-72.08 ± 34.295-82.82 ± 27.889
Week 28-71.86 ± 26.979-73.97 ± 34.922-81.60 ± 28.432
Week 32-71.80 ± 27.867-74.49 ± 34.085-81.22 ± 28.812
Week 36-73.75 ± 26.730-75.55 ± 34.652-81.62 ± 27.706
Week 40-72.04 ± 27.324-76.49 ± 32.641-84.88 ± 27.123
Week 44-73.08 ± 28.123-77.93 ± 34.758-84.54 ± 24.702
Week 48-72.93 ± 28.940-79.38 ± 34.445-86.16 ± 24.318
Week 52-75.37 ± 25.904-77.67 ± 33.804-84.52 ± 25.893
SecondaryPercentage of Participants Receiving Any Rescue Therapy by Rescue Treatment

Percentage of participants receiving any rescue therapy by rescue treatment was reported.

Time frame:
From Baseline up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Receiving Any Rescue Therapy by Rescue Treatment
percentage of participantsCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Percentage of Participants Receiving Any Rescue Therapy by Rescue Treatment13.92.75.6
SecondaryPercent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score

SCORAD is a clinical tool for assessing the severity and the extent of AD signs and symptoms. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranged from 0 (absent disease) to 103 (severe disease), a higher score indicated severe disease.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Mean · percent change
Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score
percent changeCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Week 4-35.91 ± 21.912-49.08 ± 24.712-55.04 ± 21.867
Week 8-50.33 ± 20.729-59.01 ± 20.163-61.09 ± 26.870
Week 12-58.29 ± 22.692-63.16 ± 20.228-70.53 ± 20.369
Week 16-58.98 ± 22.159-67.97 ± 18.005-68.07 ± 24.199
Week 20-58.82 ± 22.867-72.33 ± 17.542-75.46 ± 22.982
Week 24-58.83 ± 24.493-76.31 ± 13.598-76.18 ± 21.189
Week 28-65.51 ± 20.193-73.53 ± 15.894-80.23 ± 21.501
Week 32-59.52 ± 27.109-76.59 ± 15.176-75.58 ± 18.677
Week 36-66.96 ± 22.759-72.88 ± 15.971-75.29 ± 19.712
Week 40-68.57 ± 20.930-71.55 ± 17.978-74.90 ± 22.125
Week 44-73.70 ± 17.943-71.51 ± 18.440-77.16 ± 19.573
Week 48-73.29 ± 19.494-72.97 ± 24.220-76.82 ± 18.174
Week 52-72.03 ± 17.223-74.60 ± 20.382-79.09 ± 19.268
SecondaryChange From Baseline in Children's Dermatology Life Quality Index (cDLQI) For Participants >=4 Years of Age

The DLQI is a validated 10-item questionnaire covering domains including symptoms/feelings, daily activities, leisure, work/school, personal relationships, and treatment. The participant rated each question ranging from 0 (not at all) to 3 (very much) and score ranged from 0 to 30. A higher total score indicated a poorer quality of life (QoL).

Time frame:
Baseline, Week 16 and Week 52
Reported as:
Mean · score on a scale
Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) For Participants >=4 Years of Age
score on a scaleCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Week 16-9.78 ± 5.966-10.80 ± 6.411-10.52 ± 5.662
Week 52-10.72 ± 6.519-11.97 ± 6.037-12.00 ± 4.231
SecondaryChange From Baseline in Infants' Dermatology Life Quality Index (iDLQI) Score For Participants Less Than (<) 4 Years of Age

The DLQI is a validated 10-item questionnaire covering domains including symptoms/feelings, daily activities, leisure, work/school, personal relationships, and treatment. The participant rated each question ranging from 0 (not at all) to 3 (very much) and score ranged from 0 to 30. A higher total score indicated a poorer QoL.

Time frame:
Baseline, Week 16 and Week 52
Reported as:
Mean · score on a scale
Change From Baseline in Infants' Dermatology Life Quality Index (iDLQI) Score For Participants Less Than (<) 4 Years of Age
score on a scaleCohort 2: Participants Aged 2-6 Years
Week 16-13.00 ± 4.492
Week 52-13.27 ± 6.915
SecondaryChange From Baseline in Patient-Oriented Eczema Measure (POEM)

The POEM is a 7-item questionnaire that assessed disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease). A high score indicated poor QOL.

Time frame:
Baseline, Week 16 and Week 52
Reported as:
Mean · score on a scale
Change From Baseline in Patient-Oriented Eczema Measure (POEM)
score on a scaleCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Week 16-12.31 ± 6.851-13.71 ± 6.939-12.09 ± 8.013
Week 52-13.31 ± 6.398-14.77 ± 7.026-15.53 ± 7.375
SecondaryPharmacokinetic (PK)/Pharmacodynamic (PD) Relationship Between Nemolizumab Serum Concentration and Changes in PP NRS

The relationship between nemolizumab serum concentrations and changes in PP-NRS score was established using population point estimate of IC50, where IC50 is the concentration leading to half of the maximum drug-induced reduction (Imax) in PP NRS.

Time frame:
Baseline up to Week 52
Reported as:
Number · ug/mL
Pharmacokinetic (PK)/Pharmacodynamic (PD) Relationship Between Nemolizumab Serum Concentration and Changes in PP NRS
ug/mLNemolizumab: All Participants
Pharmacokinetic (PK)/Pharmacodynamic (PD) Relationship Between Nemolizumab Serum Concentration and Changes in PP NRS0.719
SecondaryPK/PD Relationship Between Nemolizumab Serum Concentration and Changes in EASI Score

The relationship between nemolizumab serum concentrations and changes in EASI score was established using population point estimate of IC50. Where, IC50 is the concentration leading to half of the maximum drug-induced reduction (Imax) in EASI score.

Time frame:
Baseline up to Week 52
Reported as:
Number · ug/mL
PK/PD Relationship Between Nemolizumab Serum Concentration and Changes in EASI Score
ug/mLNemolizumab: All Participants
PK/PD Relationship Between Nemolizumab Serum Concentration and Changes in EASI Score4.58
SecondaryPK/PD Relationship Between Nemolizumab Serum Concentration and Changes in IGA Score

The relationship between nemolizumab serum concentrations and changes in IGA score was established using the population point estimate of the slope parameter.

Time frame:
Baseline up to Week 52
Reported as:
Number · liter per micrograms (L/ug)
PK/PD Relationship Between Nemolizumab Serum Concentration and Changes in IGA Score
liter per micrograms (L/ug)Nemolizumab: All Participants
PK/PD Relationship Between Nemolizumab Serum Concentration and Changes in IGA Score0.09160
SecondaryNumber of Participants With Positive Anti-Drug Antibody (ADA) for Nemolizumab

ADA positive was defined as a sample that was evaluated as positive in both the ADA screening and confirmatory assays. ADA positive participants was defined as participants who had at least 1 positive ADA result.

Time frame:
Baseline, Week 16 and Week 52
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-Drug Antibody (ADA) for Nemolizumab
ParticipantsCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Week 16200
Week 52300

Adverse events

Collected over From Baseline up to Week 60. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Participants Aged 7-11 Year0/36 (0%)0/36 (0%)30/36 (83.3%)
Cohort 1.1: Participants Aged 7-11 Years0/37 (0%)0/37 (0%)32/37 (86.5%)
Cohort 2: Participants Aged 2-6 Years0/36 (0%)0/36 (0%)32/36 (88.9%)
Most frequent other events
Showing 10 of 103
Most frequent other events
EventCohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 Years
Upper respiratory tract infectionInfections and infestations11/3611/3716/36
NasopharyngitisInfections and infestations1/367/376/36
BronchitisInfections and infestations2/363/376/36
InfluenzaInfections and infestations0/361/376/36
VaricellaInfections and infestations1/361/375/36
ImpetigoInfections and infestations4/362/373/36
ConjunctivitisInfections and infestations0/361/373/36
GastroenteritisInfections and infestations2/362/373/36
Otitis mediaInfections and infestations1/360/373/36
PharyngitisInfections and infestations3/360/371/36

Baseline characteristics

Analysis was performed on all enrolled participants. The Enrolled Set included all participants who met the inclusion/exclusion criteria and signed the informed consent form (ICF) and all individuals who did not met the inclusion/exclusion criteria but received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 YearsTotal
Mean8.9 ± 1.518.6 ± 1.403.8 ± 1.197.1 ± 2.70
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 YearsTotal
Female17181752
Male19191957
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 YearsTotal
Hispanic or Latino3014
Not Hispanic or Latino333735105
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Participants Aged 7-11 YearCohort 1.1: Participants Aged 7-11 YearsCohort 2: Participants Aged 2-6 YearsTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0011
White363735108
More than one race0000
Unknown or Not Reported0000
08

Study locations

23 sites
  • Galderma Investigational Site #8636
    Fountain Valley, California 92708-3701, United States
  • Galderma Investigational Site #9937
    San Diego, California 92123-2746, United States
  • Galderma Investigational Site #9930
    Vista, California 92083-6031, United States
  • Galderma Investigational Site #9929
    Coral Gables, Florida 92083-6031, United States
  • Galderma Investigational Site #8142
    Indianapolis, Indiana 46250-2041, United States
  • Galderma Investigational Site #8092
    Louisville, Kentucky 40217-1444, United States
  • Galderma Investigational Site #8155
    Troy, Michigan 48084-5260, United States
  • Galderma Investigational Site #8560
    West Bloomfield, Michigan 48322, United States
  • Galderma Investigational Site #8242
    Brooklyn, New York 11203-2012, United States
  • Galderma Investigational Site #9938
    New York, New York 10032-3729, United States
  • Galderma Investigational Site #8206
    Norman, Oklahoma 73069-6301, United States
  • Galderma Investigational Site #8255
    Philadelphia, Pennsylvania 19103-4708, United States
  • Galderma Investigational Site #9931
    Beaumont, Texas 77706-3061, United States
  • Galderma Investigational Site #78218-3128
    San Antonio, Texas 78218-3128, United States
  • Galderma Investigational Site #6218
    Hellerup, 2900, Denmark
  • Galderma Investigational Site #6147
    Budapest, 1036, Hungary
  • Galderma Investigational Site #5531
    Szeged, 6720, Hungary
  • Galderma Investigational Site #5570
    Lodz, 90-265, Poland
  • Galderma Investigational Site #6237
    Ostrowiec Świętokrzyski, 27-400, Poland
  • Galderma Investigational Site #5495
    Rzeszów, 35-055, Poland
  • Galderma Investigational Site #6262
    Warsaw, 02-953, Poland
  • Galderma Investigational Site #6261
    Wroclaw, 51-685, Poland
  • Galderma Investigational Site #5896
    Esplugues de Llobregat, 0850, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Apr 2025, 46 months.

Results were first posted in May 2026, 1 year after primary completion.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 46 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2021
First posted
Jun 10, 2021
StartActual
Jun 24, 2021
Primary completionActual
Apr 28, 2025
CompletionActual
Apr 28, 2025
Results first posted
May 26, 2026
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04921345
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jun 10, 2021
Start date
Jun 24, 2021
Primary completion
Apr 28, 2025
Completion
Apr 28, 2025
Results posted
May 26, 2026
Last update
Jun 25, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nemolizumab

Start the discussion